Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 trial of AX-8 for the treatment of chronic cough patients

Next Previous
Trial Profile

Phase 2 trial of AX-8 for the treatment of chronic cough patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AX-8 (Primary)
  • Indications Cough
  • Focus Therapeutic Use

Most Recent Events

  • 21 Mar 2023 According to an Axalbion media release, based on positive findings of previous phase 2 trial of AX-8 in participants with unexplained or refractory chronic cough, the company plans to initiate a this phase 2 study of AX-8 in chronic cough patients with moderate-to-severe throat discomfort.
  • 04 Jul 2022 New trial record
  • 29 Jun 2022 According to an Axalbion media release, the company expect to initiate this trial in the first quarter of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top